Acute Kidney Injury: 9 Essential Management Steps
Clinical Practice Update — Staging, Differential Diagnosis, and Treatment in Hospitalised Adults
This is an original clinical education article informed by current guidelines and evidence. See References below for source documents.
- Clinical Focus
- Evidence-based acute kidney injury management in immunocompetent adults
- Target Audience
- Internists, hospitalists, emergency physicians, intensivists, residents
- Setting
- Emergency departments, hospital wards, intensive care
- Source Evidence
- •KDIGO Clinical Practice Guideline for Acute Kidney Injury (2012)
- •STARRT-AKI Trial — Timing of Renal Replacement Therapy (NEJM, 2020)
- •AKIKI Trial — Early vs Delayed RRT in Critical Illness (NEJM, 2016)
- •BICAR-ICU Trial — Sodium Bicarbonate in Severe Acidosis (Lancet, 2018)
Key Clinical Takeaways
Effective acute kidney injury management rests on three rapid judgements at the bedside: stage the injury, identify why it happened, and reverse what you can. A small rise in serum creatinine or a brief dip in urine output is never trivial — it signals a kidney under threat and predicts worse outcomes. The points below distil current evidence into rules you can apply today.
- 1Stage every case against both creatinine and urine output — the worse of the two sets the stage → Staging
- 2Sort the cause into prerenal, intrinsic, or postrenal before reaching for a treatment → Differential
- 3Order a bladder scan or catheter early — obstruction is fast to find and fast to fix → Differential
- 4Restore perfusion with balanced crystalloid, then stop once the patient is no longer fluid-responsive → Perfusion
- 5Hold every nephrotoxic and renally-cleared drug you safely can, and re-dose what remains → Stopping the Insult
- 6Treat hyperkalemia as the first emergency — protect the heart before correcting the number → Complications
- 7Do not start dialysis on a number alone — the evidence favours waiting for a true indication → Escalation
- 8Avoid loop diuretics to treat the injury itself — they manage fluid, not function → Complications
- 9Document the episode and arrange follow-up — survivors carry a lasting risk of chronic disease → Monitoring
Staging the Injury: The First Step in Acute Kidney Injury Management
Staging anchors all acute kidney injury management because the stage drives urgency, investigation depth, and how closely you watch the patient. The widely used framework grades severity across three tiers using two independent yardsticks: the rise in serum creatinine from a known or estimated baseline, and the fall in urine output measured over time.
A practical rule sits at the centre of staging: when the creatinine criterion and the urine output criterion disagree, the higher stage wins. A patient making almost no urine is severely injured even if the creatinine has barely moved, because the number lags the physiology by a day or more.
Stage every confirmed case using both the creatinine change and the urine output trend, and assign the worse of the two. Re-stage daily, since the level can climb after the initial assessment.
Strong Rec High Evidence KDIGO 2012Estimate a baseline creatinine from prior records where available; where none exist, use the lowest value during admission or a value back-calculated from the patient’s usual function. Flag any baseline assumption in the notes.
Moderate Rec Low Evidence KDIGO 2012Measure urine output hourly in any patient at stage 2 or higher, or whenever the trajectory is uncertain. Accurate output measurement frequently demands a urinary catheter, and the decision should weigh that benefit against infection risk.
Moderate Rec Moderate Evidence KDIGO 2012Severity Tiers at a Glance
The table below reframes the three severity tiers around what each stage means for your patient and what it should prompt you to do — not simply the cut-offs.
| Severity Tier | Creatinine Signal | Urine Output Signal | What It Should Trigger |
|---|---|---|---|
| Tier 1 (Mild) | 1.5–1.9× baseline, or a rise of at least 0.3 mg/dL within 48 hours | Below 0.5 mL/kg/h for 6–12 hours | Find the cause, review drugs and fluids, recheck within hours |
| Tier 2 (Moderate) | 2.0–2.9× baseline | Below 0.5 mL/kg/h for 12 hours or more | Escalate monitoring, consider specialist input, plan imaging |
| Tier 3 (Severe) | 3.0× baseline or more, reaching 4.0 mg/dL, or any need for dialysis | Below 0.3 mL/kg/h for 24 hours, or no urine for 12 hours | Urgent nephrology referral, screen for dialysis indications |
Building the Differential in Acute Kidney Injury Management
Sound acute kidney injury management depends on locating the problem along the nephron’s supply chain. The classic split — reduced perfusion (prerenal), parenchymal damage (intrinsic), and outflow blockage (postrenal) — remains the fastest route to the right treatment, because each category points to a different intervention.
Evaluate volume status first in every case — assess mucous membranes, jugular venous pressure, capillary refill, and a passive leg raise where appropriate. Hypoperfusion is the single most common and most reversible driver.
Strong Rec Moderate Evidence KDIGO 2012Perform a bladder scan, and place a catheter when retention is plausible, in any patient whose cause is not obvious. Outflow obstruction is quick to identify, reversible, and easy to miss in a busy admission.
Strong Rec Moderate Evidence KDIGO 2012Examine the urine in every case: send a dipstick and microscopy, and inspect the sediment. Blood and protein with cellular casts point toward an intrinsic process and should prompt early specialist involvement.
Moderate Rec Low Evidence KDIGO 2012Request renal tract ultrasound within 24 hours when obstruction is suspected, the cause is unclear, or there is no early recovery. Sooner imaging is warranted where a single functioning kidney or pyonephrosis is possible.
Moderate Rec Low Evidence KDIGO 2012Distinguishing the Three Categories
This table is organised around the bedside clues that separate the categories, paired with the move each one demands — a layout built for triage rather than reference.
| Category | Typical Triggers | Bedside Clues | First Move |
|---|---|---|---|
| Prerenal | Dehydration, sepsis, bleeding, heart failure, cirrhosis | Dry membranes, low JVP, concentrated urine, low sodium excretion | Correct perfusion; reassess response promptly |
| Intrinsic | Prolonged ischaemia, nephrotoxins, glomerular disease, interstitial nephritis | Active sediment, casts, blood and protein, rash or eosinophilia | Remove the toxin; involve nephrology for possible biopsy |
| Postrenal | Prostatic enlargement, stones, pelvic tumour, blocked catheter | Palpable bladder, anuria then polyuria, hydronephrosis on scan | Relieve the obstruction; catheterise or refer urology |
Restoring Perfusion
When hypoperfusion is the driver, restoring circulating volume and pressure is the most effective single intervention. The aim is a kidney that is once again adequately perfused — not a fixed volume of fluid delivered regardless of response.
Initiate fluid resuscitation with isotonic balanced crystalloid as first-line for hypovolaemic or septic patients, giving a measured bolus and reassessing before each further bolus.
Strong Rec Moderate Evidence KDIGO 2012Avoid routine use of hydroxyethyl starch solutions for volume expansion, given the signal toward worse renal outcomes. Reach instead for crystalloid, and reserve albumin for specific indications such as advanced liver disease.
Against High Evidence KDIGO 2012Start vasopressors alongside fluids to reach an adequate mean arterial pressure in vasodilatory shock, rather than chasing perfusion with escalating fluid volumes that risk pulmonary oedema.
Strong Rec Moderate Evidence KDIGO 2012Reassess fluid responsiveness after each bolus and stop once perfusion targets are met. Continued infusion into a non-responsive patient worsens congestion and can itself impair kidney function.
Moderate Rec Moderate Evidence KDIGO 2012Stopping the Ongoing Insult
Removing the agent that is harming the kidney is as important as anything you add. A careful medication review at the point of recognition prevents a stage 1 injury from progressing while you investigate.
Stop nephrotoxic medications wherever clinically safe, including non-steroidal anti-inflammatories, aminoglycosides, and contrast exposure that is not essential. Review every agent on the chart against the new renal picture.
Strong Rec Moderate Evidence KDIGO 2012Adjust the dose of every renally-cleared drug the patient still needs, and recalculate as function changes. Antimicrobials, anticoagulants, and many analgesics require active re-dosing to avoid accumulation and toxicity.
Strong Rec Moderate Evidence KDIGO 2012Counsel patients on temporarily withholding agents that blunt the kidney’s response to stress — including renin-angiotensin blockers and certain diuretics — during acute illness, then plan a deliberate, monitored restart.
Conditional Rec Low Evidence KDIGO 2012Common Culprits and What to Do
Rather than grouping drugs by class, this table is built around the practical question you face on the ward: for each offender, what is the mechanism, and what is the safe action?
| Offending Agent | How It Harms | Safe Action | Watch For |
|---|---|---|---|
| NSAIDs | Constrict the afferent arteriole, cutting glomerular blood flow | Stop entirely during the episode | Often over-the-counter — ask directly |
| RAAS blockers | Dilate the efferent arteriole, dropping filtration pressure | Hold during acute illness; restart with monitoring | Rising potassium after restart |
| Aminoglycosides | Accumulate in and injure tubular cells | Switch class where possible; use level-guided dosing if essential | Injury may appear after the course ends |
| Iodinated contrast | Causes transient vasoconstriction and direct tubular stress | Defer non-urgent scans; ensure good hydration if needed | Risk often overstated in mild injury |
Managing the Complications
While the cause is being addressed, the metabolic consequences of a failing kidney can themselves become life-threatening. Hyperkalaemia, acidosis, and fluid overload are the three that demand the fastest attention.
Treat hyperkalemia as an emergency when the level is high or the ECG is abnormal: stabilise the myocardium with calcium first, then shift potassium intracellularly with insulin and glucose while planning removal.
Strong Rec High Evidence KDIGO 2012Do not use loop diuretics to treat the injury itself or to hasten recovery. Reserve them for managing genuine fluid overload in a patient who still responds, and stop them if there is no diuresis.
Against Moderate Evidence KDIGO 2012Consider intravenous sodium bicarbonate for severe metabolic acidosis in selected critically ill patients, recognising the benefit is most apparent at the most severe acidosis and is not universal.
Conditional Rec Moderate Evidence BICAR-ICU 2018Monitor for fluid overload clinically and adjust intake accordingly, restricting fluids and salt once the patient is congested. Daily weights and a strict balance chart catch accumulation before it reaches the lungs.
Moderate Rec Low Evidence KDIGO 2012When to Escalate to Renal Replacement Therapy
The decision to start dialysis is one of the most consequential in acute kidney injury management, and the evidence has matured considerably. The weight of trial data now favours waiting for a concrete indication over starting pre-emptively on biochemical thresholds alone.
Initiate renal replacement therapy urgently for a life-threatening complication that is refractory to medical management — severe hyperkalaemia, intractable acidosis, refractory overload, or symptomatic uraemia.
Strong Rec High Evidence KDIGO 2012Avoid routine early dialysis based on stage or biochemistry alone in patients without an urgent indication, since a watchful strategy spares many patients a procedure they never come to need.
Moderate Rec High Evidence STARRT-AKI 2020 AKIKI 2016Consider continuous modalities over intermittent ones for haemodynamically unstable patients, where the gentler fluid and solute shifts are better tolerated. Match the modality to the patient’s stability, not to local habit.
Conditional Rec Moderate Evidence KDIGO 2012Refer to nephrology early when the cause is unclear, recovery stalls, or an intrinsic process is suspected. Timely specialist input shapes investigation, guides immunosuppression where relevant, and plans dialysis access.
Moderate Rec Low Evidence KDIGO 2012Clinical Decision Pathway
A practical, question-based route through the first hours of a new injury. Work through the questions in order.
Monitoring and Follow-Up
Recovery is not the end of the story. An episode of injury, even one that fully resolves biochemically, leaves a measurable and lasting increase in the risk of chronic kidney disease, so the follow-up plan matters as much as the acute care.
Document the episode, its stage, and its likely cause clearly in the discharge summary, and ensure the primary care team is aware. A recorded episode prompts the surveillance the patient now needs.
Moderate Rec Low Evidence KDIGO 2012Reassess kidney function within three months of any significant episode to determine whether the patient has returned to baseline or developed new chronic disease. Check both function and proteinuria at that visit.
Moderate Rec Low Evidence KDIGO 2012What to Track and When
| Parameter | When to Check | What to Look For | Common Pitfalls |
|---|---|---|---|
| Serum creatinine | Daily while unstable, then per recovery | A clear downward trend toward baseline | A plateau is not recovery — keep investigating |
| Potassium | At least daily; hourly after acute treatment | Stable and within safe range | Rebound rise after the insulin shift wears off |
| Fluid balance | Continuously — daily weight plus balance chart | Even balance once euvolaemic | Charts are often incomplete — weigh the patient |
| Function at 3 months | Outpatient review after discharge | Return to baseline or new chronic disease | Follow-up frequently never arranged at discharge |
Evidence in Context
What the major trials show, and where the practical questions remain genuinely unsettled.
Timing of Dialysis: What the Trials Settled
Large randomised trials comparing earlier with delayed initiation of dialysis in critically ill patients have consistently found no survival advantage for starting before a firm indication appears. A delayed, indication-driven strategy spares a meaningful proportion of patients dialysis altogether, because their kidneys recover in the interim.
Bicarbonate in Severe Acidosis: A Selective Benefit
Trial evidence on intravenous bicarbonate for severe metabolic acidosis in critical illness points to benefit concentrated in the subgroup with coexisting kidney injury and the most profound acidosis, where it reduced the need for dialysis. It is not a blanket therapy, and the optimal threshold remains debated.
Contrast Risk: Reassessed Downward
The risk attributed to contrast-associated AKI has been revised downward as better-controlled studies separated the contrast itself from the illness that prompted the scan. Essential imaging should rarely be withheld for fear of contrast, though sensible hydration and avoiding needless repeat exposure remain prudent.
The Long Shadow: Injury and Later Chronic Disease
A growing body of observational evidence links episodes of acute injury to a substantially higher long-term risk of chronic kidney disease and cardiovascular events, even after apparent recovery. This reframes the condition as a chronic risk marker rather than a self-limited event, and underpins the case for structured follow-up.
References
- 1.Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2(1):1–138. doi:10.1038/kisup.2012.1
- 2.STARRT-AKI Investigators. Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury. N Engl J Med. 2020;383(3):240–251. doi:10.1056/NEJMoa2000741
- 3.Gaudry S, Hajage D, Schortgen F, et al. Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit. N Engl J Med. 2016;375(2):122–133. doi:10.1056/NEJMoa1603017
- 4.Jaber S, Paugam C, Futier E, et al. Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU). Lancet. 2018;392(10141):31–40. doi:10.1016/S0140-6736(18)31080-8
How to Read the Evidence Tags
Every recommendation carries two tags — one for recommendation strength and one for evidence quality. These are Medaptly’s own simplified interpretations, designed for quick reading at the bedside.
Recommendation Strength
| Tag | What It Means |
|---|---|
| Strong Rec | High-quality evidence broadly supports this action. |
| Moderate Rec | The weight of evidence favours this action. |
| Conditional Rec | The benefit is less certain — individualise. |
| Against | Evidence shows no benefit or potential harm. |
Evidence Quality
| Tag | What It Means |
|---|---|
| High Evidence | Multiple well-designed RCTs or high-quality meta-analyses. |
| Moderate Evidence | Single RCT or large observational studies. |
| Low Evidence | Expert consensus or small studies. |